Influenza AH1N2 viruses, United Kingdom, 2001-02 influenza season. (Research).

During the winter of 2001-02, influenza AH1N2 viruses were detected for the first time in humans in the U.K. The H1N2 viruses co-circulated with H3N2 viruses and a very small number of H1N1 viruses and were isolated in the community and hospitalized patients, predominantly from children <15 years of age. Characterization of H1N2 viruses indicated that they were antigenically and genetically homogeneous, deriving the hemagglutinin (HA) gene from recently circulating A/New Caledonia/20/99-like H1N1 viruses, whereas the other seven genes originated from recently circulating H3N2 viruses. Retrospective reverse transcription-polymerase chain reaction analysis of influenza A H1 viruses isolated in the U.K. during the previous winter identified a single H1N2 virus, isolated in March 2001, indicating that H1 N2 viruses did not widely circulate in the U.K. before September 2001. The reassortment event is estimated to have occurred between 1999 and early 2001, and the emergence of H1N2 viruses in humans reinforces the need for frequent surveillance of circulating viruses.

**********

The influenza A virus genome consists of eight single-stranded RNA segments of negative sense. The segmented nature of the genome allows reassortment of genes between different influenza A strains infecting one host, which may generate novel antigenic variants and give rise to pandemics of disease in humans. Although the influenza pandemic of 1918 appears to have followed the introduction of an avian-like H1N1 virus into the human population (1), the H2N2 and H3N2 viruses responsible for the 1957 and 1968 human pandemics, respectively, were generated by reassortment between human and avian viruses (2-4). Since the last influenza pandemic of 1977, which was caused by the reemergence of the H1N1 subtype, two subtypes of influenza A (H1N1 and H3N2) have been co-circulating in humans together with influenza B viruses.

The co-circulation of influenza A H1N1 and H3N2 viruses in humans has led to sporadic reports of the isolation of H1N1-H3N2 reassortant viruses in humans (5-10). In contrast, after their isolation from pigs in 1994 (11,12), influenza A H1N2 reassortant viruses, derived from human and avian viruses, have become established in swine throughout the U.K. Influenza viruses of H1N2 subtype, derived from genetic reassortment of strains endemic in pigs, have also been established in pigs in Japan since 1978 (13,14) and, more recently, in France (15) and North America (16).

During 1988-89, several H1N2 viruses were isolated from humans in China (9,10). Genetic analysis of these reassortant viruses indicated that only the hemagglutinin (HA) gene was derived from the prevailing human H1N1 virus, whereas all other genes, including the neuraminidase (NA) gene, were introduced from the prevailing human H3N2 strain. These reassortant viruses did not spread to other countries until 2001; further isolations of influenza A H1N2 viruses in humans have not been documented.

Influenza AH1N2 viruses were detected for the first time in humans in the U.K. during the winter of 2001-02. We examine the diversity of H1N2 viruses emerging in the U.K. over a 12-month period in 2001-02. The antigenic and genetic properties of these viruses are described, as well as the relationship of reassortant viruses to parental H1N1 and H3N2 strains. Furthermore, the impact of the circulation of H1N2 viruses on disease in the community is considered, as well as the implications for diagnostic testing of influenza strains.

Materials and Methods

Epidemiologic Data

Data on the rates of community cases of influenza and influenzalike illness were collected by the Birmingham Unit of the Royal College of General Practitioners and are based on weekly returns from approximately 69 sentinel practices throughout England and Wales. The Communicable Disease Surveillance Centres in Wales and Northern Ireland and the Scottish Centre for Infection and Environmental Health provided additional data. These three mechanisms for monitoring clinical incidence of influenzalike illness cover a total population of 800,000 persons. Incidence data were recorded as new physician consultations per 100,000 persons.

Source of Isolates

Influenza viruses isolated in hospital laboratories throughout the U.K. were sent to the Enteric, Respiratory and Neurological Laboratory at the Central Public Health Laboratory for antigenic characterization. Throughout the influenza season (October-March), a subset of the clinical practices group in the Birmingham Unit of the Royal College of General Practitioners network obtained nose and throat swabs from patients who had influenzalike illness (17), which were sent directly by mail to Enteric, Respiratory and Neurological Laboratory for virus isolation and subsequent antigenic and genetic characterization. All specimens were given a laboratory sample number upon arrival.

Clinical Sample Inoculation

Combined nose and throat swab specimens in virus transport medium were treated as previously described and inoculated onto confluent Madin-Darby canine kidney cells (18). The cells were incubated at 33[degrees]C, and the medium was tested at day 7 for HA of turkey red cells.

Virus Typing

Influenza viruses were typed by using ferret antisera in hemagglutination inhibition tests as described (19). All HI tests were carried out by using 8 HA U of virus and 0.5% (v/v) turkey red blood cells. All ferret sera were treated with receptor-destroying enzyme. After typing, virus isolates were given a unique strain designation number in strict chronologic order.

Amantadine Sensitivity Assays

Susceptibility of influenza virus replication to inhibition by amantadine was determined by virus infectivity assays (20). Madin-Darby canine kidney cells were overlaid with medium containing amantadine (SigmaAldrich, Poole, Dorset, England) at a concentration of 0.1, 1.0, or 10.0 [micro]g/mL.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Nucleotide Sequencing

Viral RNA was extracted from 150-[micro]L samples by using the MagNA Pure LC total nucleic acid isolation kit, on a MagNA Pure LC extraction robot (Roche Molecular Biochemicals, Mannheim, Germany) (21). Reverse transcription was performed as previously described (20). PCR to detect N1 and N2 neuraminidase genes was performed with nested primer sets (primer sequences available on request), modified from previously described assays (22).

Viruses selected for genetic analysis are shown in Table 1. Amplification of the HA1 domain of the HA gene, the complete coding region of the NA gene and portions of the PB2, PB1, PA, NP, NS, and M genes required primers specific for the eight genes (primer sequences available by request). The regions amplified for sequence analysis were PB2, 46-487; PB1, 970-1427; PA, 499-817; HA, 84-1058; NP, 1045-1428; NA, 20-1426; M, 249-612; and NS, 146-843. PCR products were purified by using agarose gel electrophoresis and a QIA quick gel extraction kit (Qiagen Ltd, Crawley, West Sussex, England) and sequenced by using a Beckman Coulter CEQ 2000 capillary sequencer and CEQ 2000 Dye Terminator cycle sequencing Quick Start kit (Beckman Coulter, Fullerton, CA). The fragment lengths compared were PB2,442; PB 1,458; PA, 319; HA, 975; NP, 384; NA, 1407; M, 364; and NS, 698 nucleotides. Nucleotide sequences determined in this study are available from the European Molecular Biology Laboratory database (accession nos. AJ489485-AJ489502, AJ489530-AJ489559, and AJ489846-AJ489862). The nucleotide sequences for the NA, M1, and NP of A/Panama/2007/99 and A/Moscow/10/99 viruses are available in the European Molecular Biology Laboratory database under accession numbers AJ457937, AJ457966, AJ458298, AJ458297, AJ458268, and AJ458267 (23).

Phylogenetic Analysis

Sequences were analyzed by neighbor joining with the Phylip (version 3.57) suite of programs (DNA Dist and Fitch) and bootstrapping by Seqboot (24). Bootstrap values >70 were regarded as statistically significant.

Results

Epidemiology

During the period September 2001-March 2002, clinical death indices for the measurement of influenzalike illness in England and Wales did not rise above baseline levels, indicating low influenza activity (Figure 1). Very low levels of influenza activity were also recorded in Scotland (data not shown). The clinical indices of influenzalike illness activity peaked in week 6 and correlated well with the peak of influenza viruses detected and typed by Central Public Health Laboratory (data not shown; available from: URL: http://www.phls.co.uk).

[FIGURE 1 OMITTED]

In September 2001, the first isolate of the influenza season (A/Scotland/122/2001), an H1N2 virus, was isolated from a 1-year-old child. H 1N2 viruses continued to be isolated from the patients in the community and in hospitalized patients throughout the U.K. until the end of March 2002. H1N2 reassortant viruses co-circulated with a relatively equal proportion of H3N2 viruses throughout the season and a small number of H1N1 viruses. Of 420 influenza A viruses isolated and characterized in the winter of 2001-02, 54.0% were influenza A H1N2, 45.2% H3N2, and 0.7% A H1N1 subtype.

During the previous influenza season (2000-01), H1N1 and influenza B viruses co-circulated in the U.K., and no H3N2 viruses were detected. In comparison, only a small number of influenza B viruses were isolated during the winter of 2001-02 (data not shown; available from: URL: http://www.phls.co.uk).

Retrospective analysis using RT-PCR to determine the NA subtype, on 198 of 323 influenza A H1 viruses isolated during 2000-01, identified only a single H1N2 subtype virus isolated from a 9-year-old child in March 2001. Therefore, before September 2001, H1N2 viruses were not widely circulating in the U.K.

Clinical Impact of H1N2 Viruses

Despite the fact that H1N2 viruses emerged and were as frequently isolated as H3N2 viruses during the winter of 2001-02 in England, the levels of clinical influenzalike illness activity were among the lowest in the last 15 years (Figure 1). This low level indicates that the new H1N2 strain was not associated with particularly severe influenzalike illness activity. The low levels of influenzalike illness activity were also associated with correspondingly low levels of excess death rates (death from all causes), (available from: URL: http://www.phls.co.uk). More than 75% of H1N2 virus isolates were obtained from children <15 years of age (Figure 2), indicating that the major age group affected by the H1N2 viruses was young persons, possibly undergoing a primary infection. A similar proportion of H3N2 viruses isolated were also from children <15 years of age. Few H1N2 virus isolates were obtained from adults, and only a limited number were obtained from adults >65 years old. These facts suggest that the young are most susceptible to H1N2; adults and vaccinated elderly appear to have adequate protective immunity to the new sub-type. Age-specific consultation data for influenzalike illness in 2001-02 confirm that the age range most severely affected by influenzalike illness was the 5-14 age group (data not shown; available from: URL: http://www.phls.co.uk).

[FIGURE 2 OMITTED]

Antigenic Analysis of H1N2 Viruses

Antigenic characterization of the 228 H1N2 viruses isolated during 2001-02 was performed by using hemagglutination inhibition tests with postinfection ferret antisera to influenza A H1N1 and H3N2 reference and vaccine strains (Table 2). The HA gene of the H1N2 viruses was antigenically related to that of the H1N1 strain used in vaccines in 2001-02, A/NewCaledonia/20/99, and was antigenically indistinguishable from that of co-circulating A/NewCaledonia/20/99-like H1N1 viruses. No significant indication of antigenic drift in the HA genes of these viruses was observed over the period the viruses were isolated (March 2001-March 2002) (Table 2).

Sequence Analysis of HA and NA Genes

Phylogenetic analysis indicated that the HA1 sequences of the H1N2 viruses analyzed (Table 1) were most closely related (sequence similarity of 98.7% to 99.1%) to those of the H1N1 vaccine strain, A/NewCaledonia/20/99 (Figure 3). The HA1 sequences of the H1N2 viruses analyzed were very similar, exhibiting only 0%-1.2% nucleotide divergence between sequences. This divergence is in contrast to that of A/NewCaledonia/20/99-like H1N1 viruses isolated in the U.K. during 2000-01, which exhibited 0.3%-3.1% nucleotide divergence in the HA1.

[FIGURE 3 OMITTED]

Of the four amino acid differences previously observed in the HA1 sequences of H1N2 viruses isolated from various countries and compared to A/NewCaledonia/20/99 (23), all U.K. H1N2 viruses analyzed had the substitutions V169A and A193T. All but the earliest U.K. H1N2 viruses had the substitutions V178I and A218T in the HA1.

The NA genes of six H1N2 viruses analyzed (Table 1) were closely related genetically to the NA genes of recently circulating H3N2 viruses, represented by A/Moscow/10/99 (99.1% nucleotide sequence homology). All analyzed H1N2 NA gene sequences from the U.K. differed from those of A/Moscow/10/99 at the three amino acid positions observed in the NA of H1N2 viruses isolated from other parts of the world (23). In addition, with the exception of the earliest U.K. H1N2 isolate (A/England/627/2001), all analyzed H1N2 NA sequences from the U.K. had the substitution M24T, which is located in the transmembrane region of the protein (25).

We observed no mutations in the NA or HA genes that have been reported to confer resistance to NA inhibitors (26,27). None of the amino acid substitutions in the HA or NA genes resulted in the loss or creation of potential glycosylation sites in the HA or NA surface proteins of the H1N2 viruses.

Genetic Variation in the Internal Protein Genes

A region of the M1 gene of nine H1N2 isolates (Table 1) was analyzed and compared with sequences of prototype H1N1, H2N2, and H3N2 viruses, in addition to M1 gene sequence data obtained from influenza viruses isolated in the U.K. since 1951. Little sequence divergence was observed between the M1 sequences of the H1N2 viruses (0% to 0.9%), and they were most closely related to those of recent H3N2 viruses. No amino acid differences were seen between the partial M1 sequences of H1N2 viruses and those of A/Panama/2007/99, whereas one amino acid difference (R174K) was found from the M1 of A/Moscow/10/99. This substitution was first observed in H3N2 strains isolated in England in 1996 and was fixed in H3N2 viruses isolated after 1998 in the U.K.

Partial gene sequencing of the PB2, PB 1, PA, NP, and NS genes indicated that the analyzed H1N2 viruses (Table 1) also derived each of these genes from a virus of the H3N2 subtype. Very little sequence divergence was observed in these five genes of the H1N2 viruses analyzed.

Amantadine Sensitivity

The susceptibility of H1N2 virus replication to inhibition by amantadine was determined. All of the analyzed H1N2 viruses (A/Scotland/122/2001, A/England/45/2002, and A/England/63/2002) were susceptible to inhibition of virus growth by amantadine, with MIC 50 <0.1 [micro]/mL of drug.

Discussion

In the winter of 2001-02, which was a mild influenza season, influenza A H1N2 viruses were detected for the first time in the U.K. Analysis of the diversity of >200 H1N2 isolates from the U.K indicated that they were closely related antigenically and genetically and derived the HA gene from A/NewCaledonia/20/99-like H1N1 viruses, whereas the other seven genes originated from recently circulating H3N2 viruses. The H1N2 viruses were isolated throughout the influenza season and co-circulated with H3N2 viruses. In contrast to the previous winter's results, few influenza A H1N1 viruses were detected. Retrospective RT-PCR analysis of 61.4% of influenza AH1 viruses isolated during 2000-01 in the U.K. identified one H1N2 virus that had been isolated in March 2001, indicating that H1N2 viruses had not circulated widely in the U.K. before becoming established in autumn of 2001. H1N2 viruses have also been identified during 2001-02 from outbreaks of influenza in different countries in Africa, America, Asia, and Europe (28). The earliest H 1N2 viruses identified worldwide retrospectively were also isolated in March 2001 in Saudi Arabia (23).

During the past decade, influenza A H1N1 viruses have circulated intermittently in the U.K. (29). Between October 2000 and April 2001, a season of low influenza activity in the U.K., influenza A H1N1 viruses were the predominate influenza A strain circulating. Most H1N1 viruses were antigenically closely related to the vaccine strain used in the 2000-01 influenza season, A/NewCaledonia/20/99. The circulation of H1N2 reassortant viruses appears to have displaced A/NewCaledonia/20/99-like H1N1 viruses, although circulation of H1N2 does not appear to be associated with the generation of viruses with antigenically different surface proteins since the HA and NA of H1N2 viruses are antigenically similar to those of recently circulating H1N1 and H3N2 viruses. The observation that H1N2 viruses were isolated mainly from children <15 years of age suggests a preexisting immunity to H1 and N2 in the population (Figure 2). Furthermore, a similar proportion of the H3N2 viruses isolated during 2001-02 (79%) were also isolated from children <15 years old, with A/Panama/2007/99-like H3N2 viruses circulating during the same period of time as the A/NewCaledonia/20/99-like H1N1 viruses in the U.K. This conclusion is supported by the observational disease data in which the age group most severely affected by the influenza viruses circulating was the 5-14 age group and suggests that disease associated with both H1N2 and H3N2 was mainly in children acquiring a primary infection. In contrast, during the 2000-01 winter season, when influenza A H1N1 and influenza B viruses co-circulated, the disease data demonstrated that the age groups most affected by influenza viruses were the 5-14 years of age group and 15-44 years of age group (available from: URL: http://www.phls.co.uk). The age distribution of the disease data correlates with the finding that most H1N1 viruses isolated during 2000-01 were from the 5-14 years of age and 15-44 years of age groups.

Our analysis of genetic variation in the HA gene showed that seven amino acid substitutions have accumulated in the HA1 gene of influenza A H1N1 viruses between the circulation of A/Beijing/252/95-like H1N1 viruses in the U.K. and the emergence of viruses similar to the new variant, A/NewCaledonia/20/99, in October 2000. Of these, four mutations (T136S, E156G, S186P, and I194L) are located in two of the five antigenic sites (A and B) of HA1. The emergence of A/NewCaledonia/20/99-like viruses correlates with the finding that new drift variants of epidemiologic importance typically have four or more amino acid substitutions located in two or more of the antigenic sites (30). Additionally, the substitutions A193T and A218T are located in antigenic sites B and D, respectively, of HA 1, indicating the potential for further drift in the HA gene of H1N2 viruses and the possible subsequent generation of a new epidemic variant.

Although H1N1 and H3N2 subtypes have co-circulated in the human population since 1977, reassortant combinations of HA and NA subtypes are rare. Reassortant H1N2 viruses have previously been isolated from sporadic cases in humans and were not maintained in circulation in humans (9). The H1 HA-N2 NA combination may provide a better functional match between receptor-binding and receptor-destroying activities of HA and NA, respectively, perhaps providing H1N2 viruses with a fitness advantage over contemporary H1N1, H3N2, or both viruses. Postreassortment mutations in the HA gene located in the vicinity of the receptor-binding pocket have previously been shown to compensate for any imbalance between HA and NA activities and may be a factor in influenza virus evolution (31,32). Analysis of the HA1 sequences of H1N1 and H1N2 viruses isolated between December 2000 and February 2002 in the U.K. showed three substitutions at positions 178, 193, and 218 that were present only in the HA gene of the H1N2 viruses analyzed; residue 193 situated near to the HA receptor binding pocket. As these three mutations were not observed in the HA1 of recent H1N1 viruses analyzed, the substitutions may have occurred in H1N2 viruses after reassortment.

The NA genes of the H1N2 viruses are closely related genetically to the NA genes of A/Moscow/10/99-like H3N2 viruses. Of the three substitutions observed in the NA genes of H1N2 viruses compared to those of A/Moscow/10/99, residues 199 and 431 are located in antigenic sites on surface of the NA gene (33,34). Residue 199 has also been assigned to one of the 12 phylogenetically important regions of the NA gene (35). All of the amino acid residues that form the sialic acid-binding site of the NA gene were conserved in the NA of H1N2 viruses. Although changes in receptor binding and the interaction between the HA and NA proteins of H1N2 reassortants may have facilitated the emergence of the H1N2 viruses, the contribution of the internal proteins to the replicative efficiency and transmission of these viruses and their interaction with the surface glycoproteins is unknown.

The early detection and characterization of newly emerging influenza variants are two of the primary aims of the World Health Organization global influenza surveillance network. Reassortment between circulating influenza viruses leading to the emergence of a novel subtype, such as H1N2, highlights the need for subtyping of the influenza A viruses isolated. Most current diagnostic tests rely on the detection and typing of the HA of influenza viruses. Only a few laboratories perform analysis of the NA gene (as NA inhibition assays are difficult to perform) or analyze the internal proteins and the genes encoding them. The use of molecular techniques provides a rapid means for the detection and subtyping of influenza viruses, although current PCR assays target only N1 and N2 subtypes (22,36). In addition, heteroduplex mobility assays can be used to genetically characterize the HA and internal genes of influenza viruses (20,37,38). However, although molecular methods aid the rapid detection and identification of influenza viruses, virus isolation by culture is still required for antigenic characterization of influenza viruses. How influenza H1N2 reassortants will evolve and whether H1N2 viruses will be maintained in circulation in humans remain to be seen.

Table 1. Influenza A H1N1 and H1N2 U.K.
viruses selected for genetic analysis

Virus                 Sample date     Region       Source

H1N1

A/England161/2002       9/2/02        South       Hospital

H1N2

A/England/627/2001      19/3/01       South       Hospital
A/Scotland/122/2001     27/9/01      Scotland     Hospital
A/England/689/2001     24/12/01     Not known     Hospital
A/England/691/2001     21/12/01      Central      Hospital
A/England/1/2002        4/1/02       Central      Hospital
A/England/3/2002        8/1/02       Central      Hospital
A/England/5/2002        9/1/02       Central     Community
A/England18/2002        15/1/02      Central     Community
A/England/57/2002       16/1/02       South        School
A/England/73/2002       30/1/02       South        School
A/England/90/2002       24/1/02       North        School
A/England/97/2002       1/2/02        North       Hospital
A/Scotland/15/2002      19/2/02      Scotland     Hospital
575/2001 (a)           13/12/01      Central      Hospital
576/2001 (a)           13/12/01      Central      Hospital
1352/2002 (a)           24/1/02       North        School
1496/2002 (a)           30/1/02       North      Community
1660/2002 (a)           6/2/02       Central      Hospital

Virus                          Gene analyzed

H1N1

A/England161/2002                   HA

H1N2

A/England/627/2001      PB2, PB1, HA, NP, NA, M, NS
A/Scotland/122/2001         PB2, PB1, HA, NP, M
A/England/689/2001                  HA
A/England/691/2001    PB2, PB1, PA, HA, NP, NA, M, NS
A/England/1/2002                    NA
A/England/3/2002            PB2, PB1, NP, M, NS
A/England/5/2002          PB2, PB1, PA, NP, M, NS
A/England18/2002                    HA
A/England/57/2002       PB2, PB1, PA, NP, NA, M, NS
A/England/73/2002           PB2, PA, NP, M, NS
A/England/90/2002         PB2, PB1, PA, NP, M, NS
A/England/97/2002         PB2, PB1, NP, NA, M, NS
A/Scotland/15/2002                  HA
575/2001 (a)                        HA
576/2001 (a)                        HA
1352/2002 (a)                       HA
1496/2002 (a)                       NA
1660/2002 (a)                       HA

(a) Indicates where virus was not isolated by culture
from polymerase chain reaction--positive material.

Table 2. Antigenic analysis of influenza A
H1N2 by hemagglutination inhibition assays

                                      Post infection
                                      ferret antisera

                                    A/Wuhan       A/Bay
Virus                Sample date     371/95        7/95

H1N1
A/Wuhan/371/95                       1,280         320
A/Bayern7/95                          80          5,120
A/NewCaled/20/99                      160          80
A/England/70/2002      29/1/02        160          40
A/England/47/2002      29/1/02        80           40

H1N2
A/England/627/2001     19/3/01        160          80
A/Scotland/122/2001    27/9/01        160          160
A/England/691/2001    18/12/01        80           40
A/England/46/2002      29/1/02        40           <40
A/England/334/2002     6/3/02         80           <40

H3N2
A/Moscow/10/99                        <40          <40
A/Panama/2007/99                      <40          <40
A/England/687/2001    29/11/01        <40          <40
A/England/12/2002      16/1/02        <40          <40
A/Scotland/2/2002      23/1/02        <40          <40

                        Post infection ferret antisera

                      A/NewCal     A/Moscow       A/Pan
Virus                   20/99        10/99       2007/99

H1N1
A/Wuhan/371/95           80           <40          <40
A/Bayern7/95            1,280         <40          <40
A/NewCaled/20/99        5,120         <40          <40
A/England/70/2002       1,280         <40          <40
A/England/47/2002        320          <40          <40

H1N2
A/England/627/2001       640          <40          <40
A/Scotland/122/2001     2,560         <40          <40
A/England/691/2001      1,280         <40          <40
A/England/46/2002        320          <40          <40
A/England/334/2002      1,280         <40          <40

H3N2
A/Moscow/10/99           <40          640          320
A/Panama/2007/99         <40          80           640
A/England/687/2001       <40         2,560        1,280
A/England/12/2002        <40         2,560         320
A/Scotland/2/2002        <40         5,120        1,280

Acknowledgments

We acknowledge the excellent technical assistance provided by Carol Sadler, Hiral Chauhan, and Nisha Faruk. We also thank Vicky Gould for performing the amantadine sensitivity assays and Douglas Fleming for providing data on clinical incidence of influenza.

References

(1.) Reid AT, Fanning T, Janczewski T, Taubenberger J. Characterization of the 1918 "Spanish" influenza virus neuraminidase gene. Proc Natl Acad Sci U S A 2000;97:6785-90.

(2.) Schafer J, Kawaoka Y, Bean W, Suss J, Senne D, Webster R. Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir. Virology 1993;194:781-8.

(3.) Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 1978;87:13-20.

(4.) Kawaoka Y, Krauss S, Webster R. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989;63:4603-8.

(5.) Nakajima S, Cox N, Kendal A. Antigenic and genomic analysis of influenza A (H1N1) viruses from different regions of the world, February 1978-March 1980. Infect Immun 1981;32:287-94.

(6.) Young J, Palese P. Evolution of human influenza A viruses in nature: recombination contributes to genetic variation of H1N1 strains. Proc Natl Acad Sci U S A 1979;76:6647-51.

(7.) Xu X, Rocha E, Regenery H, Kendal A, Cox N. Genetic and antigenic analyses of influenza A (H1N1) viruses, 1986-1991. Virus Res 1993;28:37-55.

(8.) Cox N, Bai Z, Kendal A. Laborarory-based surveillance of influenza A (H1N1) and (H3N2) viruses in 1980-1981: antigenic and genomic analyses. Bull World Health Organ 1983;61:1459-65.

(9.) Guo Y, Xu X, Cox N. Human influenza A (H1N2) viruses isolated from China. J Gen Virol 1992;73:383-8.

(10.) Li X, Zhao C, Gao H, Zhang Y, Ishida M, Kanegae Y, et al. Origin and evolutionary characteristics of antigenic reassortant influenza A (H1N2) viruses isolated from man in China. J Gen Virol 1992;73:1329-37.

(11.) Brown I, Chakraverty P, Harris P, Alexander D. Disease outbreaks in pigs in Great Britain due to an influenza A virus of H1N2 subtype. Vet Rec 1995; 136:328-9.

(12.) Brown I, Harris P, McCauley J, Alexander D. Multiple genetic reassortment of avian and human influenza A viruses in European pigs, resulting in the emergence of an H1N2 virus of novel genotype. J Gen Virol 1998;79:2947-55.

(13.) Sugimura T, Yonemochi H, Ogawa T, Tanaka Y, Kumagai T. Isolation of a recombinant influenza virus (Hsw1N2) from swine in Japan. Arch Virol 1980;66:271-4.

(14.) Ouchi A, Nerome K, Kanegae Y, Ishida M, Nerome R, Hayashi K, et al. Large outbreaks of swine influenza in southern Japan caused by reassortant (H1N2) influenza viruses: its epizootic background and characterization of the causative viruses. J Gen Virol 1996;77:1751-9.

(15.) Marozin S, Gregory V, Cameron K, Bennett M, Valette M, Aymard M, et al. Antigenic and genetic diversity among swine influenza A H1N1 and H1N2 viruses in Europe. J Gen Virol 2002;83:735-45.

(16.) Karasin A, Olsen C, Anderson G. Genetic characterization of an H1N2 influenza virus isolated from a pig in Indiana. J Clin Microbiol 2000;38:2453-6.

(17.) Fleming D, Chakraverty P, Sadler C, Litton P. Combined clinical and virological surveillance of influenza in winters of 1992 and 1993. BMJ 1995;311:290-1.

(18.) Ellis J, Sadler C, Laidler P, Rebelo de Andrade H, Zambon M. Analysis of influenza A H3N2 strains isolated in England during 1995-1996 using polymerase chain reaction restriction. J Med Virol 1997;51:234-41.

(19.) Chakraverty P. Antigenic relationships between influenza B viruses. Bull World Health Organ 1971;45:755-66.

(20.) Ellis J, Zambon M. Combined PCR-heteroduplex mobility assay for detection and differentiation of influenza A viruses from different animal species. J Clin Microbiol 2001;39:4097-102.

(21.) Espy M, Rys P, Wold A, Uhl J, Sloan L, Jenkins G, et al. Detection of herpes simplex virus DNA in genital and dermal specimens by LightCycler PCR after extraction using the IsoQuick, MagNA Pure, and BioRobot 9604 methods. J Clin Microbiol 2001;39:2233-6.

(22.) Zhang W, Evans D. Detection and identification of human influenza viruses by the polymerase chain reaction. J Virol Methods 1991;33:165-89.

(23.) Gregory V, Bennett M, Orkhan M, Hajjar A, Varsano N, Mendelson E, et al. Emergence of influenza A H1N2 reassortant viruses in the human population during 2001. Virology 2002;300:1-7.

(24.) Felenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985;39:783-91.

(25.) Varghese J, Laver W, Colman P. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9A resolution. Nature 1983;303:35-40.

(26.) McKimm-Bresschkin J. Resistance of influenza viruses to neuraminidase inhibitors--a review. Antiviral Res 2000;47:1-17.

(27.) Mendel D, Sidwell R. Influenza virus resistance to neuraminidase inhibitors. Drug Resistance Update 1998;1:184-9.

(28.) Centers for Disease Control and Prevention. Influenza A(H1N2) viruses (update). Wkly Epidemiol Rec 2002;77:77-80.

(29.) Goddard N, Joseph C, Zambon M, Nunn M, Fleming D, Watson J. Influenza surveillance in England and Wales: October 1999 to May 2000. Commun Dis Public Health 2000;3:261-6.

(30.) Wilson I, Cox N. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990;8:737-71.

(31.) Kaverin N, Gambaryan A, Bovin N, Rudneva I, Shilov A, Khodova O, et al. Postreassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match. Virology 1998;244:315-21.

(32.) Kaverin N, Matrosovich M, Gambaryan A, Rudneva I, Shilov A, Varich N, et al. Intergenic HA-NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes. Virus Res 2000;66:123-9.

(33.) Colman P, Varghese J, Laver W. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983;303:41-4.

(34.) Air G, Els M, Brown L, Laver W, Webster R. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. Virology 1985;145:237-48.

(35.) Fanning T, Reid A, Taubenberger J. Influenza A virus neuraminidase: regions of the protein potentially involved in virus-host interactions. Virology 2000;276:417-23.

(36.) Wright K, Wilson G, Novosad D, Dimock C, Tan D, Weber J. Typing and subtyping of influenza viruses in clinical samples by PCR. J Clin Microbiol 1995;33:1180-4.

(37.) Zou S, Stansfield C, Bridge J. Identification of new influenza B virus variants by multiplex reverse transcription-PCR and the heteroduplex mobility assay. J Clin Microbiol 1998;26:1544-8.

(38.) Cooper L. Subbarao K. A simple restriction fragment length polymorphism-based strategy that can distinguish the internal genes of human H1N1, H3N2, and H5N1 influenza A viruses. J Clin Microbiol 2000;38:2579-83.

Address for correspondence: J.S. Ellis, Respiratory Virus Unit; Enteric, Respiratory and Neurological Virus Laboratory; Public Health Laboratory Service; Central Public Health Laboratory; 61 Colindale Avenue; Colindale; London NW9 5HT, U.K.; fax: [phone]; e-mail: [e-mail]

Joanna S. Ellis, * Adriana Alvarez-Aguero, ([dagger]) Vicky Gregory, ([dagger]) Yi Pu Lin, ([dagger]) A. Hay, ([dagger]) and Maria C. Zambon *

* Central Public Health Laboratory, London, United Kingdom; and ([dagger]) National Institute for Medical Research, London, United Kingdom

Dr. Ellis is a clinical scientist in the Enteric, Respiratory and Neurological Virus Laboratory, in the Public Health Laboratory Service. Her current research interests include the development of improved molecular techniques for the diagnosis of influenza infections, and molecular epidemiology of influenza viruses.